Five Prime Therapeutics Inc (FPRX) : Eventide Asset Management reduced its stake in Five Prime Therapeutics Inc by 7.97% during the most recent quarter end. The investment management company now holds a total of 1,155,200 shares of Five Prime Therapeutics Inc which is valued at $53,774,560 after selling 100,000 shares in Five Prime Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Five Prime Therapeutics Inc makes up approximately 2.77% of Eventide Asset Management’s portfolio.
Other Hedge Funds, Including , Tudor Investment Corp Et Al boosted its stake in FPRX in the latest quarter, The investment management firm added 2,035 additional shares and now holds a total of 15,120 shares of Five Prime Therapeutics Inc which is valued at $703,836. Five Prime Therapeutics Inc makes up approx 0.03% of Tudor Investment Corp Et Al’s portfolio. Wespac Advisors Socal added FPRX to its portfolio by purchasing 300 company shares during the most recent quarter which is valued at $13,965. Five Prime Therapeutics Inc makes up approx 0.01% of Wespac Advisors Socal’s portfolio.Group One Trading reduced its stake in FPRX by selling 1,500 shares or 81.04% in the most recent quarter. The Hedge Fund company now holds 351 shares of FPRX which is valued at $16,339.Oppenheimer Co Inc reduced its stake in FPRX by selling 1,352 shares or 10.42% in the most recent quarter. The Hedge Fund company now holds 11,625 shares of FPRX which is valued at $532,309. Five Prime Therapeutics Inc makes up approx 0.02% of Oppenheimer Co Inc’s portfolio. Trillium Asset Management added FPRX to its portfolio by purchasing 62,445 company shares during the most recent quarter which is valued at $3,165,337. Five Prime Therapeutics Inc makes up approx 0.20% of Trillium Asset Management’s portfolio.
Five Prime Therapeutics Inc opened for trading at $44.2 and hit $45.101 on the upside on Thursday, eventually ending the session at $44.74, with a gain of 1.73% or 0.76 points. The heightened volatility saw the trading volume jump to 3,18,099 shares. Company has a market cap of $1,268 M.
On the company’s financial health, Five Prime Therapeutics Inc reported $-0.49 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.52. The company had revenue of $9.23 million for the quarter, compared to analysts expectations of $6.31 million. The company’s revenue was up 46.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.45 EPS.
Five Prime Therapeutics Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include FPA008 FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1) receptor (CSF1R) that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b) which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation. Its partner GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.